



FEB 7 2007

Re: EXJADE
Docket No.: 2006E-0261

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Patent Extension
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 6,465,504, filed by Novartis AG, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for EXJADE (deferasirox), the human drug product claimed by the patent.

The total length of the regulatory review period for EXJADE (deferasirox) is 2,288 days. Of this time, 2,103 days occurred during the testing phase and 185 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: July 31, 1999.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on July 31, 1999.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: May 2, 2005.

FDA has verified the applicant's claim that the new drug application (NDA) for EXJADE (deferasirox) (NDA 21-882) was initially submitted on May 2, 2005.


3. The date the application was approved: November 2, 2005.

FDA has verified the applicant's claim that NDA 21-882 was approved on November 2, 2005.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, reading "Jane A. Axelrad". The signature is fluid and cursive, with the first name "Jane" and last name "Axelrad" clearly legible.

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Oona A. Jackson
Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 104
East Hanover, NJ 07936-1080